nodes	percent_of_prediction	percent_of_DWPC	metapath
Deferoxamine—Renal tubular disorder—Adefovir Dipivoxil—hepatitis B	0.148	0.148	CcSEcCtD
Deferoxamine—Transaminases increased—Entecavir—hepatitis B	0.0361	0.0361	CcSEcCtD
Deferoxamine—Serum creatinine increased—Entecavir—hepatitis B	0.0357	0.0357	CcSEcCtD
Deferoxamine—Serum creatinine increased—Adefovir Dipivoxil—hepatitis B	0.0348	0.0348	CcSEcCtD
Deferoxamine—Liver disorder—Adefovir Dipivoxil—hepatitis B	0.0314	0.0314	CcSEcCtD
Deferoxamine—Bone pain—Adefovir Dipivoxil—hepatitis B	0.0223	0.0223	CcSEcCtD
Deferoxamine—Hepatic function abnormal—Adefovir Dipivoxil—hepatitis B	0.0178	0.0178	CcSEcCtD
Deferoxamine—Anaphylactoid reaction—Entecavir—hepatitis B	0.0165	0.0165	CcSEcCtD
Deferoxamine—Renal impairment—Adefovir Dipivoxil—hepatitis B	0.0163	0.0163	CcSEcCtD
Deferoxamine—Blood creatinine increased—Entecavir—hepatitis B	0.0149	0.0149	CcSEcCtD
Deferoxamine—Blood creatinine increased—Adefovir Dipivoxil—hepatitis B	0.0146	0.0146	CcSEcCtD
Deferoxamine—Renal impairment—Telbivudine—hepatitis B	0.0137	0.0137	CcSEcCtD
Deferoxamine—Blood disorder—Lamivudine—hepatitis B	0.0122	0.0122	CcSEcCtD
Deferoxamine—Renal failure—Entecavir—hepatitis B	0.0121	0.0121	CcSEcCtD
Deferoxamine—Renal failure—Adefovir Dipivoxil—hepatitis B	0.0118	0.0118	CcSEcCtD
Deferoxamine—Bone disorder—Lamivudine—hepatitis B	0.0112	0.0112	CcSEcCtD
Deferoxamine—Abdominal discomfort—Telbivudine—hepatitis B	0.0108	0.0108	CcSEcCtD
Deferoxamine—Urinary tract disorder—Adefovir Dipivoxil—hepatitis B	0.0106	0.0106	CcSEcCtD
Deferoxamine—Connective tissue disorder—Adefovir Dipivoxil—hepatitis B	0.0106	0.0106	CcSEcCtD
Deferoxamine—Urethral disorder—Adefovir Dipivoxil—hepatitis B	0.0105	0.0105	CcSEcCtD
Deferoxamine—Immune system disorder—Entecavir—hepatitis B	0.00995	0.00995	CcSEcCtD
Deferoxamine—Renal failure—Telbivudine—hepatitis B	0.00991	0.00991	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Telbivudine—hepatitis B	0.00988	0.00988	CcSEcCtD
Deferoxamine—Neuropathy—Lamivudine—hepatitis B	0.00953	0.00953	CcSEcCtD
Deferoxamine—Connective tissue disorder—Telbivudine—hepatitis B	0.00889	0.00889	CcSEcCtD
Deferoxamine—Leukopenia—Entecavir—hepatitis B	0.00858	0.00858	CcSEcCtD
Deferoxamine—Mediastinal disorder—Telbivudine—hepatitis B	0.00816	0.00816	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Entecavir—hepatitis B	0.00811	0.00811	CcSEcCtD
Deferoxamine—Myalgia—Adefovir Dipivoxil—hepatitis B	0.00797	0.00797	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Adefovir Dipivoxil—hepatitis B	0.00791	0.00791	CcSEcCtD
Deferoxamine—Anaphylactic shock—Entecavir—hepatitis B	0.00783	0.00783	CcSEcCtD
Deferoxamine—Infection—Entecavir—hepatitis B	0.00777	0.00777	CcSEcCtD
Deferoxamine—Renal impairment—Lamivudine—hepatitis B	0.00775	0.00775	CcSEcCtD
Deferoxamine—Nervous system disorder—Entecavir—hepatitis B	0.00767	0.00767	CcSEcCtD
Deferoxamine—Skin disorder—Entecavir—hepatitis B	0.0076	0.0076	CcSEcCtD
Deferoxamine—Muscle spasms—Telbivudine—hepatitis B	0.00757	0.00757	CcSEcCtD
Deferoxamine—Nervous system disorder—Adefovir Dipivoxil—hepatitis B	0.00749	0.00749	CcSEcCtD
Deferoxamine—Thrombocytopenia—Adefovir Dipivoxil—hepatitis B	0.00748	0.00748	CcSEcCtD
Deferoxamine—Skin disorder—Adefovir Dipivoxil—hepatitis B	0.00742	0.00742	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Adefovir Dipivoxil—hepatitis B	0.00696	0.00696	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Entecavir—hepatitis B	0.00676	0.00676	CcSEcCtD
Deferoxamine—Myalgia—Telbivudine—hepatitis B	0.00671	0.00671	CcSEcCtD
Deferoxamine—Arthralgia—Telbivudine—hepatitis B	0.00671	0.00671	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Telbivudine—hepatitis B	0.00666	0.00666	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Adefovir Dipivoxil—hepatitis B	0.00659	0.00659	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Entecavir—hepatitis B	0.0064	0.0064	CcSEcCtD
Deferoxamine—Nervous system disorder—Telbivudine—hepatitis B	0.0063	0.0063	CcSEcCtD
Deferoxamine—Thrombocytopenia—Telbivudine—hepatitis B	0.00629	0.00629	CcSEcCtD
Deferoxamine—Skin disorder—Telbivudine—hepatitis B	0.00624	0.00624	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Adefovir Dipivoxil—hepatitis B	0.00624	0.00624	CcSEcCtD
Deferoxamine—Abdominal pain—Entecavir—hepatitis B	0.00619	0.00619	CcSEcCtD
Deferoxamine—Body temperature increased—Entecavir—hepatitis B	0.00619	0.00619	CcSEcCtD
Deferoxamine—Abdominal discomfort—Lamivudine—hepatitis B	0.00611	0.00611	CcSEcCtD
Deferoxamine—Body temperature increased—Adefovir Dipivoxil—hepatitis B	0.00604	0.00604	CcSEcCtD
Deferoxamine—Abdominal pain—Adefovir Dipivoxil—hepatitis B	0.00604	0.00604	CcSEcCtD
Deferoxamine—Dysuria—Lamivudine—hepatitis B	0.00596	0.00596	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Telbivudine—hepatitis B	0.00586	0.00586	CcSEcCtD
Deferoxamine—Paraesthesia—Telbivudine—hepatitis B	0.00577	0.00577	CcSEcCtD
Deferoxamine—Renal failure—Lamivudine—hepatitis B	0.00558	0.00558	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Lamivudine—hepatitis B	0.00557	0.00557	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Telbivudine—hepatitis B	0.00555	0.00555	CcSEcCtD
Deferoxamine—Pain—Telbivudine—hepatitis B	0.0055	0.0055	CcSEcCtD
Deferoxamine—Pruritus—Adefovir Dipivoxil—hepatitis B	0.0054	0.0054	CcSEcCtD
Deferoxamine—Diarrhoea—Entecavir—hepatitis B	0.00535	0.00535	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Telbivudine—hepatitis B	0.00526	0.00526	CcSEcCtD
Deferoxamine—Diarrhoea—Adefovir Dipivoxil—hepatitis B	0.00522	0.00522	CcSEcCtD
Deferoxamine—Dizziness—Entecavir—hepatitis B	0.00518	0.00518	CcSEcCtD
Deferoxamine—Abdominal pain—Telbivudine—hepatitis B	0.00508	0.00508	CcSEcCtD
Deferoxamine—Body temperature increased—Telbivudine—hepatitis B	0.00508	0.00508	CcSEcCtD
Deferoxamine—Connective tissue disorder—Lamivudine—hepatitis B	0.00501	0.00501	CcSEcCtD
Deferoxamine—Vomiting—Entecavir—hepatitis B	0.00498	0.00498	CcSEcCtD
Deferoxamine—Headache—Entecavir—hepatitis B	0.0049	0.0049	CcSEcCtD
Deferoxamine—Vomiting—Adefovir Dipivoxil—hepatitis B	0.00485	0.00485	CcSEcCtD
Deferoxamine—Headache—Adefovir Dipivoxil—hepatitis B	0.00478	0.00478	CcSEcCtD
Deferoxamine—Nausea—Entecavir—hepatitis B	0.00465	0.00465	CcSEcCtD
Deferoxamine—Immune system disorder—Lamivudine—hepatitis B	0.00461	0.00461	CcSEcCtD
Deferoxamine—Mediastinal disorder—Lamivudine—hepatitis B	0.0046	0.0046	CcSEcCtD
Deferoxamine—Pruritus—Telbivudine—hepatitis B	0.00455	0.00455	CcSEcCtD
Deferoxamine—Nausea—Adefovir Dipivoxil—hepatitis B	0.00454	0.00454	CcSEcCtD
Deferoxamine—Erythema—Lamivudine—hepatitis B	0.00444	0.00444	CcSEcCtD
Deferoxamine—Diarrhoea—Telbivudine—hepatitis B	0.0044	0.0044	CcSEcCtD
Deferoxamine—Muscle spasms—Lamivudine—hepatitis B	0.00427	0.00427	CcSEcCtD
Deferoxamine—Dizziness—Telbivudine—hepatitis B	0.00425	0.00425	CcSEcCtD
Deferoxamine—Vomiting—Telbivudine—hepatitis B	0.00409	0.00409	CcSEcCtD
Deferoxamine—Angioedema—Lamivudine—hepatitis B	0.00406	0.00406	CcSEcCtD
Deferoxamine—Headache—Telbivudine—hepatitis B	0.00403	0.00403	CcSEcCtD
Deferoxamine—Leukopenia—Lamivudine—hepatitis B	0.00397	0.00397	CcSEcCtD
Deferoxamine—Convulsion—Lamivudine—hepatitis B	0.00385	0.00385	CcSEcCtD
Deferoxamine—Nausea—Telbivudine—hepatitis B	0.00382	0.00382	CcSEcCtD
Deferoxamine—Myalgia—Lamivudine—hepatitis B	0.00378	0.00378	CcSEcCtD
Deferoxamine—Arthralgia—Lamivudine—hepatitis B	0.00378	0.00378	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—hepatitis B	0.00375	0.00375	CcSEcCtD
Deferoxamine—Anaphylactic shock—Lamivudine—hepatitis B	0.00362	0.00362	CcSEcCtD
Deferoxamine—Oedema—Lamivudine—hepatitis B	0.00362	0.00362	CcSEcCtD
Deferoxamine—Infection—Lamivudine—hepatitis B	0.0036	0.0036	CcSEcCtD
Deferoxamine—Shock—Lamivudine—hepatitis B	0.00356	0.00356	CcSEcCtD
Deferoxamine—Nervous system disorder—Lamivudine—hepatitis B	0.00355	0.00355	CcSEcCtD
Deferoxamine—Thrombocytopenia—Lamivudine—hepatitis B	0.00355	0.00355	CcSEcCtD
Deferoxamine—Skin disorder—Lamivudine—hepatitis B	0.00352	0.00352	CcSEcCtD
Deferoxamine—Hypotension—Lamivudine—hepatitis B	0.00339	0.00339	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Lamivudine—hepatitis B	0.0033	0.0033	CcSEcCtD
Deferoxamine—Paraesthesia—Lamivudine—hepatitis B	0.00325	0.00325	CcSEcCtD
Deferoxamine—Dyspnoea—Lamivudine—hepatitis B	0.00323	0.00323	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Lamivudine—hepatitis B	0.00313	0.00313	CcSEcCtD
Deferoxamine—Pain—Lamivudine—hepatitis B	0.0031	0.0031	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Lamivudine—hepatitis B	0.00296	0.00296	CcSEcCtD
Deferoxamine—Urticaria—Lamivudine—hepatitis B	0.00288	0.00288	CcSEcCtD
Deferoxamine—Abdominal pain—Lamivudine—hepatitis B	0.00286	0.00286	CcSEcCtD
Deferoxamine—Body temperature increased—Lamivudine—hepatitis B	0.00286	0.00286	CcSEcCtD
Deferoxamine—Hypersensitivity—Lamivudine—hepatitis B	0.00267	0.00267	CcSEcCtD
Deferoxamine—Pruritus—Lamivudine—hepatitis B	0.00256	0.00256	CcSEcCtD
Deferoxamine—Diarrhoea—Lamivudine—hepatitis B	0.00248	0.00248	CcSEcCtD
Deferoxamine—Dizziness—Lamivudine—hepatitis B	0.0024	0.0024	CcSEcCtD
Deferoxamine—Vomiting—Lamivudine—hepatitis B	0.0023	0.0023	CcSEcCtD
Deferoxamine—Headache—Lamivudine—hepatitis B	0.00227	0.00227	CcSEcCtD
Deferoxamine—Nausea—Lamivudine—hepatitis B	0.00215	0.00215	CcSEcCtD
